Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexium for prevention of rebleeding after endoscopic treatment of peptic ulcer
NCT00251979Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2005
- Primary completion
- Dec 2007
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in Gastrointestinal Bleeding (GIB) and peptic ulcer disease (PUD) comparing Nexium IV with Placebo IV (2 arms). Primary endpoint: Clinically Significant Rebleeding Within 72 Hours. Started Oct 2005; status: completed.
02
Drugs
esomeprazole
03
Conditions
Gastrointestinal Bleeding (GIB)peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT00251979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251979.